Stryker Books $293 Million Vascular Impairment While $3,259 Million Of Goodwill Remains Exposed

Stryker's 10-Q shows a 100-basis-point rise in the discount rate would add an $823 million charge on the remaining Peripheral Vascular goodwill.

Share
Stryker Books $293 Million Vascular Impairment While $3,259 Million Of Goodwill Remains Exposed

Stryker, which makes surgical, emergency-care and joint-replacement devices, booked a $293 million goodwill impairment on its Peripheral Vascular business in the third quarter, according to its 10-Q. About $3,259 million of goodwill still sits on that unit, and the filing's sensitivity table shows how little it would take to cut into it; shares fell 5.27% to $295.33 in Friday trading.

One rate tick, an $823 million charge

Goodwill is the premium a company pays above the value of an acquired business's assets, and it must be written down when the business is worth less than its book value. Because the unit's book value was likely above its fair value, Stryker ran an interim test built on projected discounted cash flows.

The filing then lays out what further hypothetical changes would cost. A 100 basis point (one percentage point) rise in the discount rate would add an $823 million charge. A 100 basis point cut in long-term operating margin would add $497 million, and the same cut in long-term revenue growth would add $145 million.

Stryker warns more write-downs are possible if the unit falls short of projected cash flow, revenue and profit, or if the cost of capital climbs. The prior quarter's 10-Q carried goodwill and other impairments of $1 million for the second quarter, against $293 million in the third.

Slower recovery and supply constraints

Stryker attributes the charge mainly to a reduced cash flow forecast. Operational and supply constraints in the near term, plus a slower path to growth and market recovery, drove the cut. Those inputs fed an updated long-range plan approved in the third quarter of 2026.

The unit holds Stryker's two vascular deals. Inari, bought in February 2025 for an aggregate $4,810 million net of cash acquired, makes products for venous thromboembolism, or blood clots in veins. AVS, bought in May 2026, is developing a lithotripsy platform for complex peripheral arterial disease; Stryker paid $434 million in net cash plus up to $400 million in milestones, recorded at a fair value of $271 million.

The impairment is non-deductible, which pushed the third-quarter effective tax rate to 24.5% from 16.5% a year earlier. Reported net earnings fell to $753 million, or $1.96 a share, from $859 million. Adjusted earnings per share rose 10.3% to $3.52.

Guidance cut, buyback raised

Third-quarter Vascular sales were $566 million, up 8.0% as reported. Total sales rose 7.7% to $6.5 billion, and CEO Kevin A. Lobo said in the earnings release that the quarter "did fall short of our expectations." Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90.

In October the board added $3.0 billion to the share repurchase program, and Stryker signed a deal to invest about $400 million in CMR Surgical, maker of the Versius Plus surgical robot. That deal is expected to close in the fourth quarter of 2026.

Stryker's annual goodwill test falls on October 31, the day after the filing.

Sources

More on Stryker

All Stryker (SYK) coverage →